ES2289544T3 - Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia. - Google Patents

Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia. Download PDF

Info

Publication number: ES2289544T3
Authority: ES; Spain
Prior art keywords: mia; bases; oligonucleotide; antisense; oligonucleotides
Prior art date: 2003-08-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04763992T

Other languages

English (en)

Spanish (es)

Inventor

Karl-Hermann Schlingensiepen

Reimar Schlingensiepen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Isarna Therapeutics GmbH

Original Assignee

Antisense Pharma GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-12

Filing date

2004-08-11

Publication date

2008-02-01

2004-08-11 Application filed by Antisense Pharma GmbH filed Critical Antisense Pharma GmbH

2008-02-01 Application granted granted Critical

2008-02-01 Publication of ES2289544T3 publication Critical patent/ES2289544T3/es

2024-08-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

201000001441 melanoma Diseases 0.000 title claims description 21
230000002401 inhibitory effect Effects 0.000 title claims description 10
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 84
238000012986 modification Methods 0.000 claims abstract description 40
230000004048 modification Effects 0.000 claims abstract description 40
239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 37
238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 37
239000002773 nucleotide Substances 0.000 claims abstract description 25
125000003729 nucleotide group Chemical group 0.000 claims abstract description 25
239000012634 fragment Substances 0.000 claims abstract description 3
102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 claims description 62
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 29
108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 19
206010028980 Neoplasm Diseases 0.000 claims description 18
108090000623 proteins and genes Proteins 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 15
230000005764 inhibitory process Effects 0.000 claims description 13
229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
239000002336 ribonucleotide Substances 0.000 claims description 10
206010027476 Metastases Diseases 0.000 claims description 8
229910019142 PO4 Inorganic materials 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
-1 lipid acids Chemical class 0.000 claims description 8
235000021317 phosphate Nutrition 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 7
230000003612 virological effect Effects 0.000 claims description 7
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
102000004127 Cytokines Human genes 0.000 claims description 5
108090000695 Cytokines Proteins 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
230000012010 growth Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
108091027075 5S-rRNA precursor Proteins 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
235000012000 cholesterol Nutrition 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
239000013598 vector Substances 0.000 claims description 4
206010007710 Cartilage injury Diseases 0.000 claims description 3
208000034869 Cervical myelopathy Diseases 0.000 claims description 3
201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
208000031481 Pathologic Constriction Diseases 0.000 claims description 3
102000004338 Transferrin Human genes 0.000 claims description 3
108090000901 Transferrin Proteins 0.000 claims description 3
125000002091 cationic group Chemical group 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
230000005714 functional activity Effects 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
239000003022 immunostimulating agent Substances 0.000 claims description 3
230000001506 immunosuppresive effect Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
230000009545 invasion Effects 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 3
230000036262 stenosis Effects 0.000 claims description 3
208000037804 stenosis Diseases 0.000 claims description 3
230000000638 stimulation Effects 0.000 claims description 3
239000012581 transferrin Substances 0.000 claims description 3
208000005243 Chondrosarcoma Diseases 0.000 claims description 2
102000003814 Interleukin-10 Human genes 0.000 claims description 2
108090000174 Interleukin-10 Proteins 0.000 claims description 2
206010033128 Ovarian cancer Diseases 0.000 claims description 2
208000018554 digestive system carcinoma Diseases 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims description 2
229940076144 interleukin-10 Drugs 0.000 claims description 2
PRFXRIUZNKLRHM-UHFFFAOYSA-N l-prostaglandin B2 Natural products CCCCCC(O)C=CC1=C(CC=CCCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-UHFFFAOYSA-N 0.000 claims description 2
PRFXRIUZNKLRHM-OSJNIVAESA-N prostaglandin b2 Chemical compound CCCCC[C@H](O)\C=C\C1=C(C\C=C\CCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-OSJNIVAESA-N 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
239000002525 vasculotropin inhibitor Substances 0.000 claims description 2
NXAYYSHEARRBLR-UHFFFAOYSA-N 7-(3,5-diethyl-1-methylpyrazol-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-naphthalen-1-yloxypropyl)indole-2-carboxylic acid Chemical compound CCc1nn(C)c(CC)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(O)=O)n(CCN3CCOCC3)c12 NXAYYSHEARRBLR-UHFFFAOYSA-N 0.000 claims 1
206010019909 Hernia Diseases 0.000 claims 1
102000008866 Prostaglandin E receptors Human genes 0.000 claims 1
108010088540 Prostaglandin E receptors Proteins 0.000 claims 1
230000002159 abnormal effect Effects 0.000 claims 1
125000000129 anionic group Chemical group 0.000 claims 1
230000008878 coupling Effects 0.000 claims 1
238000010168 coupling process Methods 0.000 claims 1
238000005859 coupling reaction Methods 0.000 claims 1
239000003623 enhancer Substances 0.000 claims 1
210000000496 pancreas Anatomy 0.000 claims 1
101710195116 Melanoma-derived growth regulatory protein Proteins 0.000 description 60
210000004027 cell Anatomy 0.000 description 45
238000000034 method Methods 0.000 description 22
108090000765 processed proteins & peptides Proteins 0.000 description 22
102000004196 processed proteins & peptides Human genes 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 16
238000003786 synthesis reaction Methods 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
230000000692 anti-sense effect Effects 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 11
239000011734 sodium Substances 0.000 description 11
108090001008 Avidin Chemical class 0.000 description 10
238000001802 infusion Methods 0.000 description 10
229910052757 nitrogen Inorganic materials 0.000 description 10
244000052769 pathogen Species 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
238000009472 formulation Methods 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
150000007523 nucleic acids Chemical class 0.000 description 7
239000000047 product Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
108020004414 DNA Proteins 0.000 description 6
241000700605 Viruses Species 0.000 description 6
239000011616 biotin Chemical class 0.000 description 6
229960002685 biotin Drugs 0.000 description 6
235000020958 biotin Nutrition 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000000903 blocking effect Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000002865 immune cell Anatomy 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000019034 Chemokines Human genes 0.000 description 4
108010012236 Chemokines Proteins 0.000 description 4
150000001615 biotins Chemical class 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
239000002609 medium Substances 0.000 description 4
150000008300 phosphoramidites Chemical class 0.000 description 4
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001361 intraarterial administration Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
230000007017 scission Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
YDEOXZHCPCPPJG-UHFFFAOYSA-N 8-aminonaphthalene-1,6-disulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 YDEOXZHCPCPPJG-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
102100035304 Lymphotactin Human genes 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000020307 Spinal disease Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229960002684 aminocaproic acid Drugs 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
230000004927 fusion Effects 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
108010019677 lymphotactin Proteins 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
210000002752 melanocyte Anatomy 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
150000005691 triesters Chemical class 0.000 description 2
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
XSXHTPJCSHZYFJ-MNXVOIDGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[(5s)-5-amino-6-hydrazinyl-6-oxohexyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(=O)NN)SC[C@@H]21 XSXHTPJCSHZYFJ-MNXVOIDGSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108090000171 Interleukin-18 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
238000012356 Product development Methods 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
230000018199 S phase Effects 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005600 alkyl phosphonate group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000000854 inhibitional effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229940083538 smallpox vaccine Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Oncology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES04763992T 2003-08-12 2004-08-11 Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia. Expired - Lifetime ES2289544T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03018285		2003-08-12
EP03018285		2003-08-12

Publications (1)

Publication Number	Publication Date
ES2289544T3 true ES2289544T3 (es)	2008-02-01

Family

ID=34130073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04763992T Expired - Lifetime ES2289544T3 (es)	2003-08-12	2004-08-11	Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia.

Country Status (7)

Country	Link
US (1)	US7910563B2 (de)
EP (1)	EP1660656B1 (de)
JP (1)	JP4649408B2 (de)
AT (1)	ATE369422T1 (de)
DE (1)	DE602004008085T2 (de)
ES (1)	ES2289544T3 (de)
WO (1)	WO2005014812A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004008085T2 (de)	2003-08-12	2008-04-24	Antisense Pharma Gmbh	Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia)
CN100562342C (zh) *	2006-01-17	2009-11-25	奥林格斯技术有限公司	防治流感病毒感染的寡核苷酸药物
JP2013531981A (ja)	2010-06-11	2013-08-15	アンチセンス・ファーマ・ゲーエムベーハー	選択的オリゴヌクレオチド修飾の方法
ITRM20110134A1 (it) *	2011-03-22	2012-09-23	Matteo Bordignon	Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine
EP3103450A1 (de) *	2015-06-12	2016-12-14	Friedrich-Alexander-Universität Erlangen-Nürnberg	Nicht-hydrophobe verbindungen zur behandlung von metastasen und/oder knorpeldefekten
CN105250900A (zh) *	2015-10-21	2016-01-20	宋军君	一种治疗腰椎间盘突出中药
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
WO2017138924A1 (en)	2016-02-09	2017-08-17	Autotelic Llc	Compositions and methods for treating pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0945507A1 (de) *	1998-03-27	1999-09-29	Boehringer Mannheim Gmbh	Tumorspezifische Expressionskontrollregion und deren Verwendung
WO1999065928A2 (en) *	1998-06-19	1999-12-23	Genzyme Corporation	Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
EP1133994A1 (de) *	2000-03-11	2001-09-19	Biognostik Gesellschaft für biomolekulare Diagnostik mbH	Verfahren zür Umwandlung des immunosuppresive effekts von MIA (Melanoma Inhibitory Activity)
US20040241651A1 (en) *	2000-04-07	2004-12-02	Alexander Olek	Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
DE602004008085T2 (de)	2003-08-12	2008-04-24	Antisense Pharma Gmbh	Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia)

2004
- 2004-08-11 DE DE602004008085T patent/DE602004008085T2/de not_active Expired - Lifetime
- 2004-08-11 US US10/567,879 patent/US7910563B2/en not_active Expired - Fee Related
- 2004-08-11 WO PCT/EP2004/008986 patent/WO2005014812A2/en not_active Ceased
- 2004-08-11 EP EP04763992A patent/EP1660656B1/de not_active Expired - Lifetime
- 2004-08-11 AT AT04763992T patent/ATE369422T1/de active
- 2004-08-11 ES ES04763992T patent/ES2289544T3/es not_active Expired - Lifetime
- 2004-08-11 JP JP2006522977A patent/JP4649408B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20070299022A1 (en)	2007-12-27
US7910563B2 (en)	2011-03-22
WO2005014812A3 (en)	2005-06-09
JP2007501621A (ja)	2007-02-01
EP1660656B1 (de)	2007-08-08
DE602004008085T2 (de)	2008-04-24
EP1660656A2 (de)	2006-05-31
ATE369422T1 (de)	2007-08-15
DE602004008085D1 (de)	2007-09-20
JP4649408B2 (ja)	2011-03-09
WO2005014812A2 (en)	2005-02-17

Publication	Publication Date	Title
US20250145997A1 (en)	2025-05-08	Antisense Nucleic Acids
US20250360089A1 (en)	2025-11-27	Nanoparticle formulations for delivery of nucleic acid complexes
ES2808049T3 (es)	2021-02-25	Acido nucleico antisentido
JP7353301B2 (ja)	2023-09-29	肝臓外送達
KR102644053B1 (ko)	2024-03-06	펩티드 올리고뉴클레오티드 콘주게이트
ES2649817T3 (es)	2018-01-15	Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
ES2323252T3 (es)	2009-07-09	Procedimiento de preparacion de un oligonucleotido antisentido.
ES2765463T3 (es)	2020-06-09	Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne
ES2569558T3 (es)	2016-05-11	Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
US10758558B2 (en)	2020-09-01	Hybrid oligonucleotides and uses thereof
JP2021046396A (ja)	2021-03-25	ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
ES2742654T3 (es)	2020-02-17	Oligonucleótidos antisentido modificados hidrofóbicamente que comprenden un grupo cetal
JP2000501414A (ja)	2000-02-08	生体分子の細胞取り込みを高めるリガンド
JP2021500016A (ja)	2021-01-07	アンチセンスオリゴマー化合物
ES2289544T3 (es)	2008-02-01	Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia.
BR112019023650A2 (pt)	2020-06-02	Agentes rnai para inibir a expressão de alfa-enac e métodos de uso
CN117916374A (zh)	2024-04-19	用于寡核苷酸剂的基于寡核苷酸的递送载体及其使用方法
JP2018518148A (ja)	2018-07-12	ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除
TW202327658A (zh)	2023-07-16	具有二胺支架的用於靶向遞送治療劑的多價配體簇
JP2000512630A (ja)	2000-09-26	２’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体
KR20250011918A (ko)	2025-01-22	Mapt 발현을 억제하기 위한 조성물 및 방법
US20250242036A1 (en)	2025-07-31	Trans-membrane delivery systems and uses thereof
CA2882268A1 (en)	2015-08-17	Polynucleotide-poly(diol) conjugates, process of preparation and uses thereof
HK40106602A (zh)	2024-09-13	用於寡核苷酸剂的基於寡核苷酸的递送载体及其使用方法
CA3003267C (en)	2025-11-04	Nanoparticle formulations for delivery of nucleic acid complexes